India Biopsy Devices Market

India Biopsy Devices Market Analysis

The India Biopsy Devices Market size is estimated at USD 0.11 million in 2025, and is expected to reach USD 0.13 million by 2030, at a CAGR of 2.76% during the forecast period (2025-2030).

Factors such as increasing preference for minimally invasive procedures, an increase in the number of cancer cases worldwide, and initiatives undertaken by the government for diagnosis are expected to drive market growth in India. For instance, according to a study by the Federation of Indian Chambers of Commerce & Industry (FICCI), published in October 2022, the reported cancer incidence in India in 2022 was between 19 and 20 lakh, whereas the real incidence was 1.5 to 3 times higher than the reported cases. Thus, the high burden of cancer cases in the country is expected to increase the demand for early diagnosis, which is expected to drive the growth of the market over the forecast period.

Furthermore, an increase in the geriatric population in India is another reason for the market growth. For instance, according to the India Ageing Report 2023, in South Asia, India's aging population was on a moderate trajectory, with projections indicating that the proportion of elderly individuals will rise to 20% by 2050 and 36.1% by 2100. The geriatric population in India is likely to be prone to chronic diseases like cancer, which is expected to drive market growth over the forecast period.

Furthermore, the use of biopsy devices in healthcare facilities to improve cancer care in India may further accentuate the market growth over the forecast period. For instance, in January 2023, Sri Ramachandra Medical Centre commissioned a vacuum-assisted breast biopsy and excision technology for benign breast tumors without any surgery in a daycare procedure. Hence, the objective of developing uniform standards of patient care for the prevention, diagnosis, and treatment of cancer in these centers is expected to impact the market's growth over the forecast period.

Thus, owing to the increase in investments and government initiatives to support cancer care and the rise in cancer cases, the market studied is expected to witness notable growth in India over the forecast period. However, product recalls and the availability of alternative techniques are expected to hinder market growth over the forecast period.

India Biopsy Devices Market Trends

The Aspiration Biopsy Needles Segment is Expected to Witness a Positive Growth During the Forecast Period

Fine needle aspiration (FNA) is one of the widely used diagnostic tools in India. It differs from large bore cutting needle biopsy, as FNA utilizes 22- to 27-gauge needles. The doctor inserts a thin, hollow needle through the skin and into the suspected area, and the syringe attached to the needle suctions out a small sample of cells and sometimes fluid. These needles are most commonly used to biopsy newly identified masses in the breast, the thyroid, suspicious lymph nodes, or suspicious skin masses.

Factors such as an increase in cancer surgical procedures and a high prevalence of cancer cases among the Indian population are expected to drive market growth over the forecast period. For instance, according to the article published in October 2022 in the Indian Journal of Medical Research, lung and breast cancers were the leading sites of cancer in males and females, respectively, in the country the same year. Approximately 0.2 million breast cancer cases were reported in India in 2022. Due to the high number of cancer cases in the country, the demand for aspiration biopsy needles is likely to rise, thereby contributing to the segment growth over the forecast period.

Furthermore, an increase in research studies demonstrating the importance and advantages of aspiration biopsy needles is expected to favor the market growth over the forecast period. For instance, according to a study conducted by researchers in India in January 2024 in the Journal of Cancer Research and Therapeutics, fine needle aspiration in biopsy procedures boasts several advantages, including user-friendliness, cost-effectiveness, avoidance of hospitalization, speed, and precision. Ensuring the sample's adequacy is vital for obtaining precise results. Additionally, the study revealed a diagnostic accuracy rate of up to 95% for bone lesions, positioning the needle aspiration procedure as a superior choice for biopsy.

Thus, owing to the rise in breast cancer cases and the increase in benefits offered by aspiration needles in biopsy, the segment studied is expected to witness significant growth over the forecast period.

The Lung Biopsy Segment is Expected to Witness Healthy Growth in the Market During the Forecast Period

The lung biopsy segment is expected to witness significant growth in the market studied, owing to the increase in lung cancer cases and government initiatives to educate the Indian population to undergo early diagnosis. Lung cancer is one of the most prevalent forms of cancer in India. For instance, according to an article published in October 2022 in the Indian Journal of Medical Research, 0.1 million cases of lung cancer were detected in India in 2022. Furthermore, the increasing prevalence of smoking and the use of tobacco products in India is expected to increase the burden of lung cancer, thereby boosting market growth. For instance, according to the July 2022 update of the Foundation for a Smoke-Free World, approximately 100 million people aged 15 years and more smoked tobacco in India. Also, as per the same source, the prevalence of smoking was high in men as compared to women. Thus, a high prevalence of smokers in India is likely to raise the risk of lung cancer, which is expected to bolster segment growth over the forecast period.

Moreover, an increase in awareness campaigns and early detection programs for lung cancer in India is expected to promote the adoption of biopsy devices, which is likely to propel the segment growth over the forecast period. For instance, in November 2023, Promega India initiated free breast and lung cancer screening drives at the MCD Community Hall, Mayur Vihar, Delhi, and Indo Gulf Hospital, Sector-19, Noida, to create awareness among the people of vulnerable communities regarding the importance of early detection and treatment of these conditions. Furthermore, in November 2023, Zydus Lifesciences and Guardant Health agreed to jointly promote the Guardant360 portfolio of liquid and tissue biopsy tests across India and Nepal.

Hence, due to the increase in lung cancer cases and the rise in awareness campaigns by government/private agencies to aid early diagnosis, the lung biopsy segment is expected to witness significant growth over the forecast period.

India Biopsy Devices Industry Overview

The Indian biopsy devices market is semi-consolidated due to the presence of a few companies operating globally and regionally. A few of the major companies in the market are B. Braun SE, Cardinal Health Inc., Edges Medicare Pvt. Ltd, Advin Health Care, and Desco Medical India.

India Biopsy Devices Market Leaders

India Biopsy Devices Market News

• July 2024: Sir H N Reliance Foundation installed one of the first MR fusion prostate biopsy equipment in Maharashtra. This device, utilizing MRI-blended biopsy techniques, paves the way for precise treatment and care. While traditional machines boast an accuracy of only 30% to 40%, the MR fusion prostate biopsy equipment achieves a remarkable 90% accuracy in early-stage prostate cancer detection.
• January 2024: Dr Ravi Teja, an assistant professor of radiology at Niloufer Hospital, was granted the patent for a multi-functional biopsy device that seamlessly integrates two types of sample collection methods, including fine needle aspiration.